Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Colorectal Cancer Screening Beyond Primary Care: A Community-Based FIT Distribution Model Serving a Safety-Net Hospital Population.

Cancer medicine·2026

Same author

Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.

Drug and alcohol dependence·2026

Same author

Resident Comfort Managing Menstrual Suppression in Gender Diverse Adolescents Across Family Medicine, Pediatrics, and Obstetrics and Gynecology Specialties: A Cross-Sectional Survey Study.

Journal of pediatric and adolescent gynecology·2026

Same author

Incidence, factors, and resultant management associated with small bowel diverticular perforation: A retrospective review.

American journal of surgery·2026

Same author

Clavulanic Acid Attenuated Cocaine Craving in Individuals with Cocaine Use Disorder.

Psychopharmacology bulletin·2026

Same author

A Review of Vagus Nerve Stimulation for Disease: Comprehensive Theory and Evidence for Mechanisms of Action.

Comprehensive Physiology·2026

Search research articles

Related Experiment Video

Updated: May 20, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.

Dale Han¹, Daohai Yu, Xiuhua Zhao

¹Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Annals of Surgical Oncology

|July 7, 2012

Summary

Sentinel lymph node biopsy (SLNB) is recommended for thin melanomas ≥0.76 mm due to metastasis risk. Indications for thinner melanomas (<0.76 mm) require further definition.

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Related Experiment Videos

Last Updated: May 20, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Area of Science:

Oncology
Dermatology
Surgical Pathology

Background:

Consensus is lacking on sentinel lymph node biopsy (SLNB) for thin melanomas (≤1 mm).
This study evaluates SLNB in thin melanomas to identify predictors of nodal metastasis.

Purpose of the Study:

Determine factors predicting nodal metastases in thin melanomas.
Evaluate the utility of SLNB in patients with thin melanomas.

Main Methods:

Retrospective review of 271 patients with thin melanomas undergoing SLNB (2005-2010).
Analysis of clinicopathologic characteristics correlated with nodal status and patient outcomes.
Inclusion of 13 additional patients with nodal recurrence as the first event.

Main Results:

Sentinel lymph node (SLN) positivity was 8.1% overall (22/271).
Melanomas ≥0.76 mm showed 8.4% SLN positivity (5% T1a, 13% T1b).
Mitotic rate (≥1/mm²) and ulceration significantly correlated with nodal disease.

Conclusions:

SLNB is justified for thin melanomas ≥0.76 mm, with metastasis rates of 8.4%.
Further research is needed to define SLNB indications for melanomas <0.76 mm.